Pharmacogenetics in health-care practice

Pharmacy World and Science

Volumn 26, Issue 5, 2004, Pages 253-255

  Maitland Van Der Zee, Anke Hilse ^a   Klungel, Olaf H ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Health care; Pharmacogenetics; Pharmacy

Indexed keywords

ABC TRANSPORTER; ATYPICAL ANTIPSYCHOTIC AGENT; CARDIOVASCULAR AGENT; CLOZAPINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLIZING ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MERCAPTOPURINE; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALZHEIMER DISEASE; BIOTRANSFORMATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; ENZYME ACTIVITY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GENE INTERACTION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE; HEALTH SERVICE; HUMAN; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICOLEGAL ASPECT; NOTE; PHARMACOGENETICS; PHENOTYPE; RISK ASSESSMENT; SIDE EFFECT; SOCIAL ASPECT;

HUMANS; PHARMACOGENETICS; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY HEALTH CARE;

EID: 4644265853     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAR.0000042927.71408.d3     Document Type: Note

References (28)

1. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-5.
3. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315: 137-55.
4. Nebert DW, Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 1999; 56: 247-58.
5. van der Weide J, Steijns LS. Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 1999; 36: 722-9.
6. Bullock P. Viewpoint-pharmacogenetics and its impact on drug development. Drug Benefit Trends 1999; 11: 53-54.
7. Bailey D, Bondar A, Furness LM. Pharmacogenomics - it's not just pharmacogenetics. Curr Opin Biotechnol 1998; 9: 595-601.
8. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-7.
9. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131: 174-9.
10. Schillevoort I, de Boer A, van der Weide J, Steijns LSW, Roos RAC, Jansen PAF, Leufkens HGM. Antipsychotic-induced extrapyrimidal syndromes and cytochrome P450-2D6 genotype. Pharmacogenetics 2002; 12: 235-40.
11. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000; 14 (4): 567-72.
12. Corominas H, Baiget M. Clinical utility of thiopurine s-methyltransferase genotyping. Am J Pharmacogenomics 2004; 4 (1): 1-8.
13. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS Pharmsci 2000; 2: 4.
14. Arranz M, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M et al. Pharmacogenetic prediction of clozapine respons. Lancet 2000; 355: 1615-16.
15. Cohen BM, Bongard V. Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs. Psychopharmacology (Berl) 1999; 141: 6-10.
16. Nakagawa, K, Ishizaki T. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol Ther 2000; 86: 1-28.
17. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation [see comments]. Lancet 1994; 344: 1453-7.
18. Roses AD. Pharmacogenetics and future drug development and delivery. Lancet 2000; 355: 1358-61.
19. Carmena R, Roederer G, Mailloux H, Lussier-Cacan S, Davignon J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993; 42: 895-901.
20. Maitland-van der Zee AH et al. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics 2003; 13: 219-23.
21. Poirier J et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 12260-4.
22. Maitland-van der Zee A, de Boer A, Leufkens HGM. Pharmacogenetics and the role of the pharmacist. Journal of Research in Pharmaceutical Economics 2001; 11: 143-150.
23. Melzer D, Zimmern R. Genetics and medicalisation. BMJ 2002; 324: 863-4.
24. Brock TP et al. Pharmacogenomics: implications and considerations for pharmacists. Pharmacogenomics 2003; 4: 321-30.
25. Report Pharmacogenetics: ethical issues, September 2003. www.nuffieldbioethics.org/pharmacogenetics (5 August 2004).
26. Veenstra DL, Higashi MK, Philips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmsci 2000; 2: article 29.
27. Maitland-van der Zee AH et al. Economic evaluation of testing for angiotensin converting enzyme (ACE) genotype before starting HMG-CoA reductase therapy in men. Pharmacogenetics 2004; 14: 1-8.
28. Vandenbroucke JP et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127-30.